Thus, mutations and deletions of IFNγ pathway-related proteins on tumor cells, such as IFNγ receptors and receptor chains, resulting in resistance to immunotherapy, which is a key factor of primary and acquired immune resistance (94–96). The gene discussed is IFNG; the disease is neoplasm.